- Home
- PSF vs FHTX Comparison
PSF vs FHTX Comparison
Compare PSF & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSF
- FHTX
- Stock Information
- Founded
- PSF 2010
- FHTX 2015
- Country
- PSF United States
- FHTX United States
- Employees
- PSF N/A
- FHTX N/A
- Industry
- PSF Investment Managers
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- PSF Finance
- FHTX Health Care
- Exchange
- PSF Nasdaq
- FHTX Nasdaq
- Market Cap
- PSF 236.8M
- FHTX 278.1M
- IPO Year
- PSF N/A
- FHTX 2020
- Fundamental
- Price
- PSF $20.42
- FHTX $5.56
- Analyst Decision
- PSF
- FHTX Strong Buy
- Analyst Count
- PSF 0
- FHTX 6
- Target Price
- PSF N/A
- FHTX $11.33
- AVG Volume (30 Days)
- PSF 25.0K
- FHTX 103.3K
- Earning Date
- PSF 01-01-0001
- FHTX 08-05-2025
- Dividend Yield
- PSF 7.69%
- FHTX N/A
- EPS Growth
- PSF N/A
- FHTX N/A
- EPS
- PSF N/A
- FHTX N/A
- Revenue
- PSF N/A
- FHTX $24,173,000.00
- Revenue This Year
- PSF N/A
- FHTX $33.60
- Revenue Next Year
- PSF N/A
- FHTX $5.87
- P/E Ratio
- PSF N/A
- FHTX N/A
- Revenue Growth
- PSF N/A
- FHTX N/A
- 52 Week Low
- PSF $16.00
- FHTX $2.95
- 52 Week High
- PSF $20.19
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- PSF 52.23
- FHTX 55.83
- Support Level
- PSF $20.39
- FHTX $4.75
- Resistance Level
- PSF $20.45
- FHTX $5.30
- Average True Range (ATR)
- PSF 0.14
- FHTX 0.35
- MACD
- PSF -0.04
- FHTX 0.03
- Stochastic Oscillator
- PSF 41.03
- FHTX 90.04
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.